1 / 9

Angiotensin Converting Enzymes (ACE) Inhibitors Market Insights

Angiotensin converting enzymes inhibitors are used to for the treatment of various medical conditions such as hypertension, coronary artery disease, heart failure, diabetes, chronic kidney diseases, scleroderma, and migraines. Frequently prescribed angiotensin converting enzyme (ACE) inhibitors are benazepril, perindopril, trandolapril, captopril, enalaopril, lisinopril, and ramipril. ACE inhibitors are the first choice drugs for the treatment of hypertension.

PrashilCMI
Télécharger la présentation

Angiotensin Converting Enzymes (ACE) Inhibitors Market Insights

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Coherent Market Insights Market Research and Business Consulting Services https://www.coherentmarketinsights.com/ COVID-19 Impact Tracker

  2. Angiotensin Converting Enzymes (ACE) Inhibitors Market Insights Angiotensin converting enzymes inhibitors are used to for the treatment of various medical conditions such as hypertension, coronary artery disease, heart failure, diabetes, chronic kidney diseases, scleroderma, and migraines. Frequently prescribed angiotensin converting enzyme (ACE) inhibitors are benazepril, perindopril, trandolapril, captopril, enalaopril, lisinopril, and ramipril. ACE inhibitors are the first choice drugs for the treatment of hypertension.  The global angiotensin converting enzymes (ACE) inhibitors market was valued at US$ 11,693.6 million in 2017, and is expected to witness a CAGR of 0.8% during the forecast period (2018 – 2026).

  3. Figure 1. Global Angiotensin Converting Enzymes (ACE) Inhibitors Market Value Analysis (US$ Mn) and Y-o-Y Growth (%) Source: Coherent Market Insights Analysis (2019) Increasing prevalence of hypertension is expected to drive growth of the angiotensin converting enzymes (ACE) inhibitors market Increasing prevalence of hypertension is one of the major drivers for the angiotensin converting enzymes (ACE) inhibitors market growth. For instance, according to World Health Organization’s (WHO) report, in 2018, around 207 million people including 112 million men and 95 million women suffer from hypertension, annually in India. Moreover, increasing number of research and development activities for improvement of cardiovascular functions during pregnancy is expected to propel the angiotensin converting enzyme (ACE) inhibitors market growth.

  4. Angiotensin Converting Enzymes (ACE) Inhibitors Market - Regional Analysis Regional segmentation of the global angiotensin converting enzymes (ACE) inhibitors market comprises North America, Latin America, Europe, Asia Pacific, Middle East, and Africa. North America angiotensin converting enzymes (ACE) inhibitors market is expected to account for the largest market share, owing increasing approval activities by the U.S. Food and Drug Administration (FDA). For instance, in August 2016, Silvergate Pharmaceutical Inc. received the U.S. FDA approval for its Qbrelis, containing Lisinopril, an oral solution 1 mg/ml. This drug is indicated for the treatment of hypertension in adult and in children. Moreover, Europe is expected to gain significant share in the global angiotensin converting enzymes (ACE) inhibitors market over the forecast period, owing to increasing product launch in this region. For instance, in September 2012, France-based CevaSanteAnimale S. A. launched its new combination drug, Benazepril and Spironolactone Tablet, for the treatment of heart failure in humans as well as in dogs.

  5. Figure 2: Global Angiotensin Converting Enzymes (ACE) Inhibitors Market Value (US$ Mn), By Region, 2018 Source: Coherent Market Insights Analysis (2019) Angiotensin Converting Enzymes (ACE) Inhibitors Market - Competitive Landscape Key players operating in the angiotensin converting enzymes (ACE) inhibitors market include, Pfizer, Inc., AstraZeneca Pharmaceutical Company, Novartis AG, Daiichi Sankyo Company, Ltd., United Therapeutics Corporation, Sanofi S.A., Johnson & Johnson Services, Inc., Merck KGaA, Takeda Pharmaceutical Company, and  Bayer AG.

  6. About Us: • Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. •  What we provide: • Customized Market Research Services • Industry Analysis Services • Business Consulting Services • Market Intelligence Services • Long term Engagement Model • Country Specific Analysis

  7. Request Sample Report • Request Customization • Download PDF Brochure • Talk to Analyst • CMI Services • CMI Latest Insights • CMI Blogs

  8. Contact Us Mr. Shah Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1-206-701-6702 Email: sales@coherentmarketinsights.com

  9. Thank You! Kindly follow CMI Social Media Profiles for the latest company updates Facebook Linkedin Twitter https://www.coherentmarketinsights.com/

More Related